Cargando…

Inclisiran: First Approval

Inclisiran (Leqvio(®); Novartis) is a first-in-class, cholesterol-lowering small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine carbohydrates (GalNAc). Inclisiran received its first approval in December 2020 in the EU for use in adults with primary hypercholesterolaemia (he...

Descripción completa

Detalles Bibliográficos
Autor principal: Lamb, Yvette N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900795/
https://www.ncbi.nlm.nih.gov/pubmed/33620677
http://dx.doi.org/10.1007/s40265-021-01473-6